Advanced malignant solid tumor
Conditions
Interventions
1:docetaxel 75 mg/m2, d1
q21d+oxaliplatin100mg/m2, d1
q21d+capecitabine1000mg/m2, bid, d1-7
q21d
2:docetaxel 75 mg/m2, d1
q21d+oxaliplatin120mg/m2, d1
3:docetaxel 75 mg/m2, d1
q21doxaliplatin100mg/m2, d1
q21d+capecitabine1250mg/m2, bid, d1-7
Sponsors
Affiliated Cancer Hospital of Guangxi Medical University/Cancer Hospital of Guangxi Zhuang Autonomous Region
Eligibility
Sex/Gender
All
Age
36 Years to 64 Years
Inclusion criteria
Inclusion criteria: (1) Patients who were histologically or cytologically confirmed to have advanced head and neck squamous cell carcinoma, esophageal or gastric cancer; (2) Patients were not previously treated with docetaxel, oxaliplatin or capecitabine, and their last chemotherapy cycle was completed at least 4 weeks prior to enrollment; (3) Patients aged 18 to 70 years; (4) ECOG PS (Eastern Cooperative Oncology Group Performance Status) =4.0*10^9/L, ANC >=2.0*10^9/L, HB >=100 g/L, PLT >=100.0*10^12/L; (7) Patients with AST and ALT <=2.5*UNL (upper normal limit) in liver function tests and normal renal function; (8) Patients who had provided informed consent; (9) The trial was approved by the local ethics committees in all participating institutions.
Exclusion criteria
Exclusion criteria: (1) Patients with allergies to docetaxel, oxaliplatin or capecitabine; (2) Patients who could not take oral capecitabine; (3) Patients with malabsorption syndromes; (4) Patients with serious heart and liver dysfunctions; (5) Patients with brain metastases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| DLT;MTD; | — |
Countries
China
Contacts
Public ContactZhi-hui Liu
Affiliated Cancer Hospital of Guangxi Medical University
Outcome results
None listed